Korro Bio
Korro Bio

Korro Bio

Biotechnology
WebsiteSEC
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

$198.2M

Market Cap • 9/11/2026

2014

(12 years)

Founded

2023

(3 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,9

P/S

83,2

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

8,6

EPS

—

Market Cap

Market Cap

198,2M

EV

125,4M

EV/Revenue

52,6

EV/EBITDA

-1,2

EV/EBIT

-1,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-43,3%

Total Yield

-43,3%

Payout

0%

Retained Earnings

-422,4M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

2155,5%

Capex/Revenue

13,3%

Capex/D&A

12,3%

Capex/OCF

-0,5%

SBC/OCF

—

% PPE

9,2%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-41,7%

CAGR Op. Income 5Y

15,6%

CAGR Net Income 5Y

14,7%

CAGR EPS 5Y

-33,9%

CAGR OCF 5Y

-0,2%

Leverage

N.D./EBITDA

0,7

Debt/Equity

0%

Current Ratio

9,6

Quick Ratio

9,1

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium